Search results
AstraZeneca started at buy at Goldman, which rates GSK a neutral
Morningstar· 4 days agoGoldman Sachs started coverage of AstraZeneca at buy as it rated rival pharmaceutical company GSK a neutral. Analysts led by Rajan Sharma said AstraZeneca
AstraZeneca stock upgraded by Goldman, 27% upside seen By Investing.com
Investing.com· 4 days agoOn Thursday, Goldman Sachs (NYSE:GS) initiated coverage on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN)...
AstraZeneca shares target raised by Argus on new drug approvals By Investing.com
Investing.com· 4 days agoOn Thursday, AstraZeneca PLC (NASDAQ:LON:AZN) shares received an updated price target from a market...
Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca By...
Investing.com· 4 days agoIn their first quarter 2024 earnings call, Cellectis, a biopharmaceutical company, presented a...
This Pharma Stock Is Poised to Keep Outperforming the S&P 500 | The Motley Fool
The Motley Fool· 4 days agoAstraZeneca (AZN 1.23%), recognized as the world's sixth-largest pharmaceutical entity by market...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 3 days agolongest-serving chief executive, Pascal Soriot, has no plans to step down for now as the company...
AstraZeneca-Daiichi's Enhertu follow-up Dato-DXd unable to prove overall survival benefit in phase 3
FierceBiotech· 6 days agoDaiichi Sankyo and antibody-drug conjugate (ADC) partner AstraZeneca have already filed their...
Commerce Bank Trims Holdings in AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 5 days agoCommerce Bank lessened its stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 10.6% in the 4th quarter, according to the company in its most recent filing with the Securities ...
AstraZeneca (NASDAQ:AZN) Now Covered by Analysts at The Goldman Sachs Group
ETF DAILY NEWS· 3 days agoThe Goldman Sachs Group assumed coverage on shares of AstraZeneca (NASDAQ:AZN – Free Report) in a research report report published on Thursday morning, Marketbeat Ratings ...
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
Zacks· 5 days agoAstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.